Transdermal Scopolamine Ointment for Reducing Salivation in Pediatric and Adolescent Patients with Brain Tumors

<b><i>Background:</i></b> Patients with advanced brain tumors often experience dysphagia and excessive drooling, leading to respiratory complications and a reduced quality of life. We evaluated the clinical utility of transdermal scopolamine (TS) in pediatric patients with brain tumors. <b><i>Methods:</i></b> A 5.0% scopolamine ointment was prepared in-house and applied once daily to the mastoid regions behind the ears. <b><i>Results:</i></b> Five patients (four children and one adolescent) with brain tumors received TS treatment. All patients had low Lansky/Karnofsky performance status scores, ranging from 20 to 40. Within two weeks of treatment, four patients showed objective improvements, including reduced suctioning and oxygen requirements and alleviation of respiratory symptoms. No severe or unexpected adverse events related to TS were observed. Four patients were able to transition to home-based care. <b><i>Conclusions:</i></b> The findings of this study suggest that TS may be a safe and effective option for managing salivation in this population.